Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials

Autor:	Yoshiya Tanaka, Tatsuya Atsumi, Daniel Aletaha, Beatrix Bartok, Alena Pechonkina, Ling Han, Kahaku Emoto, Shungo Kano, Vijay Rajendran, Tsutomu Takeuchi
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	Filgotinib Adalimumab Methotrexate Rheumatoid arthritis Diseases of the musculoskeletal system RC925-935
Zdroj:	Rheumatology and Therapy, Vol 10, Iss 1, Pp 161-185 (2022)
Druh dokumentu:	article
ISSN:	2198-6576 2198-6584
DOI:	10.1007/s40744-022-00503-3
Popis:	Abstract Introduction We conducted a post hoc analysis of efficacy and safety of filgotinib stratified by estimated radiographic progression rate before baseline (BL) in patients with rheumatoid arthritis (RA) who had inadequate response to methotrexate (MTX; FINCH 1; NCT02889796) or were naïve to it (FINCH 3; NCT02886728). Methods Radiographic progression rate was BL-Modified Total Sharp Score (mTSS) divided by RA duration (BL mTSS/year); estimated rapid radiographic progression (e-RRP) was BL change in mTSS/year ≥ 5; and estimated nonrapid radiographic progression (e-NRRP) was BL mTSS/year
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/5ad3c011326f47e39cc3a991b6b2f59f Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.